Gonadotropin releasing hormone agonists: Expanding vistas
Gonadotropin-releasing hormone (GnRH) agonists are derived from native GnRH by amino acid substitution which yields the agonist resistant to degradation and increases its half-life. The hypogonadotropic hypogonadal state produced by GnRH agonists has been often dubbed as "pseudomenopause"...
Main Author: | Navneet Magon |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2011-01-01
|
Series: | Indian Journal of Endocrinology and Metabolism |
Subjects: | |
Online Access: | http://www.ijem.in/article.asp?issn=2230-8210;year=2011;volume=15;issue=4;spage=261;epage=267;aulast=Magon |
Similar Items
-
Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs
by: Maira Huerta-Reyes, et al.
Published: (2019-10-01) -
Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China
by: Yinghao Sun, et al.
Published: (2020-07-01) -
A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain
by: Sallwa M. Alshehre, et al.
Published: (2020-04-01) -
Triggering ovulation with gonadotropin-releasing hormone agonist versus human chorionic gonadotropin in polycystic ovarian syndrome. A randomized trial
by: Amr Hassaan Farag, et al.
Published: (2015-12-01) -
Effects of continuous treatment with gonadotropin-releasing hormone during the anovulatory season on gonadotropin secretion, follicular dynamics and ovulation in the mare
by: Morton, Stephanie
Published: (2005)